NASDAQ:NVCR NovoCure (NVCR) Stock Price, News & Analysis → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Free NVCR Stock Alerts $15.63 +0.99 (+6.76%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$14.38▼$16.0550-Day Range$13.07▼$17.2952-Week Range$10.87▼$83.60Volume2.81 million shsAverage Volume1.55 million shsMarket Capitalization$1.67 billionP/E RatioN/ADividend YieldN/APrice Target$34.13 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get NovoCure alerts: Email Address NovoCure MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.56 Rating ScoreUpside/Downside118.3% Upside$34.13 Price TargetShort InterestBearish5.75% of Float Sold ShortDividend StrengthN/ASustainability-1.15Upright™ Environmental ScoreNews Sentiment0.25Based on 30 Articles This WeekInsider TradingSelling Shares$127,161 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.73) to ($1.79) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.89 out of 5 starsMedical Sector255th out of 939 stocksSurgical & Medical Instruments Industry32nd out of 97 stocks 3.3 Analyst's Opinion Consensus RatingNovoCure has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on 5 buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $34.13, NovoCure has a forecasted upside of 118.3% from its current price of $15.63.Amount of Analyst CoverageNovoCure has only been the subject of 4 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted5.75% of the float of NovoCure has been sold short.Short Interest Ratio / Days to CoverNovoCure has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in NovoCure has recently decreased by 1.77%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldNovoCure does not currently pay a dividend.Dividend GrowthNovoCure does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreNovoCure has received a 68.17% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for cancer", "Brain cancer medication", and "Cabozantinib" products. See details.Environmental SustainabilityThe Environmental Impact score for NovoCure is -1.15. Previous Next 2.4 News and Social Media Coverage News SentimentNovoCure has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 30 news articles for NovoCure this week, compared to 5 articles on an average week.Search InterestOnly 7 people have searched for NVCR on MarketBeat in the last 30 days. This is a decrease of -22% compared to the previous 30 days.MarketBeat Follows13 people have added NovoCure to their MarketBeat watchlist in the last 30 days. This is an increase of 225% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, NovoCure insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $127,161.00 in company stock.Percentage Held by InsidersOnly 5.67% of the stock of NovoCure is held by insiders.Percentage Held by Institutions84.61% of the stock of NovoCure is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for NovoCure are expected to decrease in the coming year, from ($1.73) to ($1.79) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NovoCure is -8.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NovoCure is -8.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNovoCure has a P/B Ratio of 4.61. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… About NovoCure Stock (NASDAQ:NVCR)NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.Read More NVCR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NVCR Stock News HeadlinesMarch 29, 2024 | americanbankingnews.comNovoCure (NASDAQ:NVCR) Trading 4.8% Higher After Analyst UpgradeMarch 28, 2024 | fool.comWhy Novocure Stock Is Jumping TodayMarch 29, 2024 | WealthPress (Ad)$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…March 28, 2024 | americanbankingnews.comNovoCure (NASDAQ:NVCR) Given New $24.00 Price Target at HC WainwrightMarch 28, 2024 | americanbankingnews.comNovoCure (NASDAQ:NVCR) Receives Neutral Rating from WedbushMarch 27, 2024 | seekingalpha.comNovoCure: Sell The METIS-Inspired RallyMarch 27, 2024 | markets.businessinsider.comNuanced Phase 3 Results Prompt Cautious Hold Rating for NovoCure’s StockMarch 27, 2024 | msn.comNovocure's device shown to slow cancer progression in the brain in trialMarch 29, 2024 | Crypto 101 Media (Ad)Major Elon Musk Crypto Leak RevealedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.March 27, 2024 | markets.businessinsider.comPeeling Back The Layers: Exploring NovoCure Through Analyst InsightsMarch 27, 2024 | marketwatch.comNovocure’s stock surges after positive results in brain-cancer trialMarch 27, 2024 | markets.businessinsider.comNovocure Shares Rise After Phase 3 METIS Trial Met Primary EndpointMarch 27, 2024 | msn.comNovocure Stock Soars, Its Lung Cancer Electric Field Treatment Slows Progression To Brain, Data ShowsMarch 27, 2024 | proactiveinvestors.comNovoCure device slows spread of lung cancer to brain in late-stage study; shares riseMarch 27, 2024 | marketwatch.comNovocure Shares Surge Premarket on Phase 3 TTFields StudyMarch 27, 2024 | investing.comNovocure shares jump after trial meets primary endpointMarch 27, 2024 | msn.comNovocure's lung cancer therapy succeeds in late-stage trialMarch 27, 2024 | businesswire.comZai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung CancerMarch 27, 2024 | businesswire.comMETIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung CancerMarch 24, 2024 | americanbankingnews.comNovoCure (NASDAQ:NVCR) Stock Price Down 6%March 21, 2024 | americanbankingnews.comJPMorgan Chase & Co. Raises NovoCure (NASDAQ:NVCR) Price Target to $17.00March 20, 2024 | finance.yahoo.comNVCR Dec 2025 17.500 callMarch 20, 2024 | finance.yahoo.comNVCR Jan 2026 20.000 callMarch 15, 2024 | finance.yahoo.comNVCR Apr 2024 10.000 putMarch 15, 2024 | finance.yahoo.comNVCR Apr 2024 17.500 callMarch 12, 2024 | markets.businessinsider.comNovoCure’s Clinical Trial Results: Subgroup Promise Amidst Cautioned Market OutlookMarch 11, 2024 | businesswire.comINNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGOSee More Headlines Receive NVCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NovoCure and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/22/2024Today3/28/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:NVCR CUSIPN/A CIK1645113 Webwww.novocure.com Phone441534756700FaxN/AEmployees1,453Year FoundedN/APrice Target and Rating Average Stock Price Target$34.13 High Stock Price Target$51.00 Low Stock Price Target$15.00 Potential Upside/Downside+118.3%Consensus RatingModerate Buy Rating Score (0-4)2.56 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($1.95) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-207,040,000.00 Net Margins-40.65% Pretax Margin-37.65% Return on Equity-51.63% Return on Assets-17.90% Debt Debt-to-Equity Ratio1.57 Current Ratio5.78 Quick Ratio5.56 Sales & Book Value Annual Sales$509.34 million Price / Sales3.29 Cash FlowN/A Price / Cash FlowN/A Book Value$3.39 per share Price / Book4.61Miscellaneous Outstanding Shares107,090,000Free Float101,021,000Market Cap$1.67 billion OptionableOptionable Beta0.41 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. William F. Doyle (Age 62)Executive Chairman Comp: $1.52MMr. Asaf Danziger (Age 58)CEO & Director Comp: $1.7MMs. Ashley Cordova (Age 45)Chief Financial Officer Comp: $933.39kMr. Wilhelmus C. M. Groenhuysen (Age 66)Chief Operating Officer Comp: $1.01MMr. Frank LeonardExecutive VP & President of Novocure OncologyProf. Yoram Palti M.D. (Age 86)Ph.D., Founder & CTO Comp: $282.51kDr. Moshe Giladi Ph.D. (Age 54)Chief Science Officer Ms. Ingrid GoldbergVP of Investor RelationsMr. Barak Ben Arye (Age 47)General Counsel Mr. Michael Puri (Age 55)Chief Human Resources Officer More ExecutivesKey CompetitorsAtriCureNASDAQ:ATRCLeMaitre VascularNASDAQ:LMATMiMedx GroupNASDAQ:MDXGAlphatecNASDAQ:ATECParagon 28NYSE:FNAView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 122,105 shares on 3/11/2024Ownership: 9.113%Wilhelmus Cm GroenhuysenSold 1,217 sharesTotal: $19,484.17 ($16.01/share)Frank X LeonardSold 840 sharesTotal: $13,448.40 ($16.01/share)Wilhelmus Cm GroenhuysenSold 2,107 sharesTotal: $33,775.21 ($16.03/share)Frank X LeonardSold 1,679 sharesTotal: $26,914.37 ($16.03/share)View All Insider TransactionsView All Institutional Transactions NVCR Stock Analysis - Frequently Asked Questions Should I buy or sell NovoCure stock right now? 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NovoCure in the last year. There are currently 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" NVCR shares. View NVCR analyst ratings or view top-rated stocks. What is NovoCure's stock price target for 2024? 9 equities research analysts have issued 1-year target prices for NovoCure's shares. Their NVCR share price targets range from $15.00 to $51.00. On average, they predict the company's share price to reach $34.13 in the next twelve months. This suggests a possible upside of 118.3% from the stock's current price. View analysts price targets for NVCR or view top-rated stocks among Wall Street analysts. How have NVCR shares performed in 2024? NovoCure's stock was trading at $14.93 at the beginning of the year. Since then, NVCR shares have increased by 4.7% and is now trading at $15.63. View the best growth stocks for 2024 here. When is NovoCure's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our NVCR earnings forecast. How were NovoCure's earnings last quarter? NovoCure Limited (NASDAQ:NVCR) released its quarterly earnings data on Thursday, February, 22nd. The medical equipment provider reported ($0.45) earnings per share for the quarter, topping the consensus estimate of ($0.53) by $0.08. The medical equipment provider had revenue of $133.80 million for the quarter, compared to analysts' expectations of $133.80 million. NovoCure had a negative net margin of 40.65% and a negative trailing twelve-month return on equity of 51.63%. The company's revenue for the quarter was up 4.2% on a year-over-year basis. During the same period in the prior year, the company posted ($0.36) EPS. What ETFs hold NovoCure's stock? ETFs with the largest weight of NovoCure (NASDAQ:NVCR) stock in their portfolio include Amplify BlueStar Israel Technology ETF (ITEQ), VanEck Israel ETF (ISRA), Principal Healthcare Innovators ETF (BTEC), Invesco Nasdaq Biotechnology ETF (IBBQ) and iShares U.S. Medical Devices ETF (IHI).First Trust Nasdaq Pharmaceuticals ETF (FTXH). What guidance has NovoCure issued on next quarter's earnings? NovoCure updated its fourth quarter 2023 earnings guidance on Monday, January, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $133.8 million-$133.8 million, compared to the consensus revenue estimate of $129.3 million. What is Asaf Danziger's approval rating as NovoCure's CEO? 17 employees have rated NovoCure Chief Executive Officer Asaf Danziger on Glassdoor.com. Asaf Danziger has an approval rating of 90% among the company's employees. What other stocks do shareholders of NovoCure own? Based on aggregate information from My MarketBeat watchlists, some companies that other NovoCure investors own include Chembio Diagnostics (CEMI), Prospect Capital (PSEC), Calumet Specialty Products Partners (CLMT), NVIDIA (NVDA), Two Harbors Investment (TWO), BlackRock Capital Investment (BKCC), Viper Energy (VNOM), Roku (ROKU), Salesforce (CRM) and Block (SQ). Who are NovoCure's major shareholders? NovoCure's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (9.13%), Vanguard Group Inc. (9.11%), Capital International Investors (8.29%), Baillie Gifford & Co. (4.53%), Capital World Investors (3.07%) and Price T Rowe Associates Inc. MD (2.11%). Insiders that own company stock include Asaf Danziger, Ashley Cordova, Ely Benaim, Frank X Leonard, Frank X Leonard, Gabriel Leung, Jeryl L Hilleman, Martin J Madden, Pritesh Shah, Todd Christopher Longsworth, Uri Weinberg, Wilhelmus Cm Groenhuysen and William F Doyle. View institutional ownership trends. How do I buy shares of NovoCure? Shares of NVCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NVCR) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingFed launches fourth dollar overhaulStansberry ResearchThe 3rd Revolution in WarfareWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NovoCure Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.